Radiant Skin, Stronger Immunity, and Improved Liver Health UV Protection Skin Luminosity Liver Health Provides powerful antioxidant protection Lightens and evens skin tone Protects against UV damage Enhances the effects of sunscreen Inhibits melasma & hyperpigmentation Reduces oxidative stress and inflammation Prevents premature skin ageing Promotes skin radiance and increases suppleness Reduces collagen degradation Improves skin quality Enhances after-laser aesthetic improvements Reduces oxidative stress and inflammation Improves liver functions Benefits NAFLD & NASH Normalises liver detoxification potential Radiant Skin, Stronger Immunity, and Improved Liver Health UV Protection Provides powerful antioxidant protection Lightens and evens skin tone Protects against UV damage Enhances the effects of sunscreen Inhibits melasma & hyperpigmentation Skin Luminosity Reduces oxidative stress and inflammation Prevents premature skin ageing Promotes skin radiance and increases suppleness Reduces collagen degradation Improves skin quality Enhances after-laser aesthetic improvements Liver Health Reduces oxidative stress and inflammation Improves liver functions Benefits NAFLD & NASH Normalises liver detoxification potential Who is Crystaceuticals SOD Glutathione Plus For
Mechanism mapping (Nature Communications, 2025) Identified the disordered p53 transactivation domain as the binding target, adding structural detail to the mechanism
Because of its antioxidant nature, Glutathione is generally well-tolerated by sensitive skin
Even if the peptide is not the root cause, it can still raise risk by masking mole warning signs and pushing people into more sun time
Mechanistic Understanding Gaps Fundamental aspects of combination pharmacology require clarification[23]: Receptor-level interactions between components unknown (synergistic, additive, or antagonistic) Optimal dosing sequences and escalation protocols not scientifically established Tissue-specific distribution of combined formulation requires investigation Metabolic pathway interactions between incretin and amylin systems incompletely mapped Whether combination provides true synergy or simply additive effects remains unclear Population-Specific Considerations Research gaps exist for specific populations[24]: Renal impairment effects on peptide clearance inadequately studied Hepatic dysfunction impact on safety profile unclear Elderly populations (over 75 years) underrepresented in trials Racial and ethnic diversity in study populations limited Patients with cardiovascular disease require additional safety data Regulatory & Competitive Sport Status FDA Position Neither component has received FDA approval for any indication as of September 2025: GLP3 in phase 3 development for obesity and type 2 diabetes (TRIUMPH trials ongoing) Cagrilintide in phase 3 development as part of CagriSema combination Combined GLP3 + cagrilintide formulation not under regulatory review Not legally available for medical use, compounding, or human consumption No established therapeutic use basis for the combination Both peptides remain investigational drugs under active clinical development by their respective manufacturers
